Michael Bukhalo

1.1k total citations · 1 hit paper
18 papers, 668 citations indexed

About

Michael Bukhalo is a scholar working on Immunology, Dermatology and Molecular Biology. According to data from OpenAlex, Michael Bukhalo has authored 18 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 8 papers in Dermatology and 3 papers in Molecular Biology. Recurrent topics in Michael Bukhalo's work include Psoriasis: Treatment and Pathogenesis (10 papers), Dermatology and Skin Diseases (5 papers) and Nonmelanoma Skin Cancer Studies (3 papers). Michael Bukhalo is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (10 papers), Dermatology and Skin Diseases (5 papers) and Nonmelanoma Skin Cancer Studies (3 papers). Michael Bukhalo collaborates with scholars based in United States, Canada and Australia. Michael Bukhalo's co-authors include Andrew Blauvelt, Stephen K. Tyring, Alan Menter, Melinda Gooderham, Mary Flack, Sudha Visvanathan, B Berner, James G. Krueger, J.‐P. Lacour and Nathan Bennett and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

Michael Bukhalo

16 papers receiving 653 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

2017 392 citations Kim Papp, Andrew Blauvelt et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Michael Bukhalo

Since Specialization

Citations

This map shows the geographic impact of Michael Bukhalo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Bukhalo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Bukhalo more than expected).

Fields of papers citing papers by Michael Bukhalo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Bukhalo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Bukhalo. The network helps show where Michael Bukhalo may publish in the future.

Co-authorship network of co-authors of Michael Bukhalo

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Bukhalo. A scholar is included among the top collaborators of Michael Bukhalo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Bukhalo. Michael Bukhalo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study 2025 ·Journal of the American Academy of Dermatology ·Kim Papp, (unknown), Howard Sofen, Michael Bukhalo, Elisa Muscianisi, (unknown), (unknown), (unknown), Roman G. Rubio, (unknown), Andrew Blauvelt	0
2	Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body 2025 ·JAMA Dermatology ·Melinda Gooderham, Javier Alonso‐Llamazares, Jerry Bagel, Neal Bhatia, Michael Bukhalo, Janet DuBois, Laura K. Ferris, Lawrence Green, Leon Kircik, Benjamin Lockshin, Wei Jing Loo, Kim Papp, Jennifer Soung, (unknown), Scott Snyder, (unknown), David Krupa, Patrick Burnett, David R. Berk, David H. Chu	1
3	A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement 2024 ·Journal of the American Academy of Dermatology ·Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Brad Glick, Mar Llamas‐Velasco, (unknown), (unknown), Tianyu Zhan, (unknown), Kevin Douglas, (unknown), Ramon Espaillat, Robert Bissonnette	2
4	Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study 2024 ·Dermatology and Therapy ·Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, (unknown), Georgios Kokolakis, Andreas Pinter, (unknown), (unknown), (unknown), (unknown), Ahmed M. Soliman, Simone Rubant, Diamant Thaçi	0
5	Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5) 2022 ·Journal of Cutaneous Medicine and Surgery ·David Rosmarin, Marta Casillas, (unknown), (unknown), Evangeline Pierce, Hong Zhang, Michael Bukhalo, Stacy Smith	4
6	Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes 2022 ·SKIN The Journal of Cutaneous Medicine ·Bruce Strober, Michael Bukhalo, April W. Armstrong, David M. Pariser, Leon Kircik, Sepideh Parhami, Paul Montgomery, Tobin J. Dickerson	1
7	Efficacy and safety of ingenol disoxate gel in field treatment of actinic keratosis on full face, scalp or large area (250 cm2) on the chest: results of four phase 3 randomized controlled trials 2020 ·Dermatology Online Journal ·Brian Berman, Michael Bukhalo, C. William Hanke, Mikala F. Jarner, Thomas Larsson, Daniel M. Siegel, Torsten Skov, Rolf‐Markus Szeimies	2
8	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis breakdown → 2017 ·New England Journal of Medicine ·Kim Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G. Krueger, J.‐P. Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen K. Tyring, B Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J. Padula	392
9	A seamless phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp 2017 ·British Journal of Dermatology ·Jerrold Weiss, Ulrich Martin, Michael Bukhalo, Marie Louise Østerdal, B K Bang, C. William Hanke	9
10	Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study 2017 ·Journal of the European Academy of Dermatology and Venereology ·Robert Bissonnette, Richard P. Haydey, (unknown), Charles Lynde, Michael Bukhalo, Joseph F. Fowler, Isabelle Delorme, (unknown), Melinda Gooderham, Yves Poulin, (unknown), (unknown), Ian Landells, David M. Pariser	40
11	Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest. 2017 ·PubMed ·C. William Hanke, Brian Berman, Neil A. Swanson, David M. Pariser, Jonathan Weiss, Michael Bukhalo, Torsten Skov, John Villumsen, Daniel M. Siegel	3
12	Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A) 2016 ·Journal of the European Academy of Dermatology and Venereology ·Kristina Callis Duffin, Jerry Bagel, Michael Bukhalo, I Clement', (unknown), Fangyi Zhao, Anne Gill, Beth A. Pangallo, Catherine L Shuler, Lotus Mallbris, Kimberley Jackson	35
13	A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis 2016 ·American Journal of Clinical Dermatology ·April W. Armstrong, Michael Bukhalo, Andrew Blauvelt	37
14	Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience 2016 ·Medical Devices Evidence and Research ·Kristina Callis Duffin, Michael Bukhalo, (unknown), David Shrom, Fangyi Zhao, (unknown), Anne Gill, Beth A. Pangallo, Catherine L Shuler, Jerry Bagel	17
15	Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. 2016 ·PubMed ·Mark Lebwohl, Stephen K. Tyring, Michael Bukhalo, Javier Alonso‐Llamazares, Martin Olesen, D. Lowson, Paul S. Yamauchi	54
16	Photodynamic therapy with methyl aminolaevulinate 80 mg g⁻¹for severe facial acne vulgaris: a randomized vehicle-controlled study 2015 ·British Journal of Dermatology ·(unknown), Lawrence F. Eichenfield, Michael Bukhalo, Gabriel N. Waterman, Michael Jarratt, (unknown)	28
17	Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. 2013 ·PubMed ·Alan Menter, Linda Stein Gold, Michael Bukhalo, (unknown), Steven Kempers, (unknown), Cecilia Ganslandt, John Villumsen, Mark Lebwohl	32
18	Leukocytoclastic vasculitis induced by use of glyburide: a case of possible cross-reaction of a sulfonamide and a sulfonylurea. 2003 ·PubMed ·Michael Bukhalo, Nathalie C. Zeitouni, Richard T. Cheney	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact